论文部分内容阅读
为研究替莫唑胺联合放疗对胶质瘤患者血管内皮生长因子(VEGF)、白介素-8(IL-8)表达的影响,本研究选取2010年7月至2011年6月我院收治的60例胶质瘤患者,根据随机抽签法分为试验组和对照组,每组30例。对照组使用放疗方式,试验组患者在此基础上口服替莫唑胺,150 mg·m~(-2)·d~(-1),连续服用5 d,4周为1个治疗周期,根据患者具体情况给药4~6个周期。比较两组患者治疗前后VEGF、IL-8水平、生活质量改善情况,评判两组患者的临床疗效、生存率、不良反应。结果显示,治疗后,试验组的总有效率86.67%(26/30)显著高于对照组63.33%(19/30),差异有统计学意义(p<0.05)。试验组的VEGF、IL-8水平显著低于对照组,(65.93±3.55)pg/m L比(85.85±3.26)pg/m L,(20.81±1.92)pg/m L比(31.11±3.10)pg/m L(p<0.05);试验组的KPS评分明显高于对照组,(83.06±5.16)分比(71.34±2.82)分(p<0.05);试验组1年、2年、3年的生存率显著高于对照组,90.00%(27/30)比73.33%(22/30),80.00%(24/30)比50.00%(15/30),66.67%(20/30)比36.67%(11/30);中位复发时间晚于对照组,(24.32±2.32)月比(16.23±1.45)月,差异均有统计学意义(p<0.05);试验组和对照组的不良反应率比较无显著性差异,16.67%(5/30)比20.00%(6/30)(p>0.05)。研究结果表明替莫唑胺联合放疗能明显降低胶质瘤患者VEGF、IL-8表达,临床疗效良好,可提高患者的生活质量和生存率,安全性高。
In order to study the effect of temozolomide combined with radiotherapy on the expression of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) in glioma patients, we selected 60 glial masses from July 2010 to June 2011 in our hospital. Tumor patients were divided into experimental group and control group according to random sampling method, 30 cases in each group. In the control group, the patients in the test group were treated with oral temozolomide (150 mg · m ~ (-2) · d ~ (-1)) for 5 consecutive days. The patients in the test group were given one treatment cycle for 4 weeks. According to the patients’ specific conditions Dosing 4 to 6 cycles. The levels of VEGF and IL-8 in both groups before and after treatment were compared, and the quality of life was improved. The clinical efficacy, survival rate and adverse reactions in both groups were evaluated. The results showed that after treatment, the total effective rate of the experimental group was significantly higher than that of the control group (86.67%, 26/30) (63.33%, 19/30), the difference was statistically significant (p <0.05). The levels of VEGF and IL-8 in the experimental group were significantly lower than those in the control group (65.93 ± 3.55 pg / m L, 85.85 ± 3.26 pg / m L, 20.81 ± 1.92 pg / m L vs 31.11 ± 3.10) (P <0.05). The KPS score of the experimental group was significantly higher than that of the control group (83.06 ± 5.16) (71.34 ± 2.82) (p <0.05). The experimental group had 1, 2 and 3 years The survival rates of 90.00% (27/30) vs 73.33% (22/30), 80.00% (24/30) to 50.00% (15/30), 66.67% (20/30) to 36.67 % (11/30). The median recurrence time was later than the control group (24.32 ± 2.32) months (16.23 ± 1.45) months, the difference was statistically significant (p <0.05). The adverse reactions of the experimental group and the control group There was no significant difference between the two groups (16.67% (5/30) vs 20.00% (6/30)) (p> 0.05). The results show that temozolomide combined with radiotherapy can significantly reduce the expression of VEGF, IL-8 in glioma patients with good clinical efficacy, can improve the quality of life and survival of patients with high safety.